Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

Find My GLP-1 PathSee my GLP-1 options & prices

How to Get Retatrutide in 2026: Availability, the 2 Verified Paths, and Who Qualifies

By The RX Index Editorial Team · Last verified October 2026

You can't get retatrutide with a regular U.S. prescription yet. It isn't FDA-approved. Two documented paths to Lilly-made retatrutide exist: a clinical trial, or a narrow expanded-access request made by your treating doctor. Both have strict rules, and neither guarantees access. Here's how to get retatrutide through those paths—and what can rule them out. (FDA, Lilly)

Here's the catch: a trial listed as open may not have a retatrutide spot near you. When we checked the federal trial registry on October 16, 2026, one Lilly retatrutide trial was marked Recruiting. It's a fatty-liver study lasting a little over four years. The table below shows the access claims people run into, and which ones are documented.

RX Index Decision Verdict: Check these two documented doors first. If neither opens for you, make a plan with your prescriber around available care, not a maybe in 2027.

  • Best for checking retatrutide access now: adults who may meet all five expanded-access rules below, or people with high-risk fatty liver disease who can reach a study site.
  • Not ideal for: anyone hoping for a regular prescription, a fast start, or a cheaper online version.
  • The factor that matters most: whether a study team can offer screening, or your own doctor can make an expanded-access request for Lilly and FDA to review.

If your retatrutide supply stopped, see what to do if your retatrutide supply stopped.

For the PCOS-specific evidence question, see retatrutide for PCOS.

Looking for a GLP-1 that's available today?

Retatrutide isn't available by prescription yet. Answer a few questions to see a suggested route among current GLP-1 options and the prices to compare.

Find my GLP-1 path

Free · about 2 minutes · no signup

How to get retatrutide: each access path, side by side

Two documented paths to Lilly-made retatrutide exist in the U.S.: a clinical trial or a doctor-requested expanded-access exception. Neither is a normal pharmacy prescription. FDA says retatrutide cannot be compounded under federal law; a telehealth visit or a research-use label does not make retail treatment lawful (FDA, Lilly Medical).

People use the word "available" to mean a lot of different things. This map answers each one.

How to get retatrutide: each access path, side by side
Access path or offerU.S. status nowIs it Lilly-made retatrutide?Who can use itCost to youSource, checked Oct 16, 2026
Lilly clinical trialDocumented research accessYes in the retatrutide group; a trial may assign another treatment or placebo (a look-alike without the study drug)People who fit the study and sub-study rules at a reachable site that is screeningAsk the study team what's covered and what's reimbursedClinicalTrials.gov search
Lilly expanded accessDocumented, case-by-case accessYesAdults who meet all five posted rules; your treating doctor asks, and further review is requiredLilly says the drug is free. Visits, labs, and travel: askNCT07629401, Lilly Medical
Federal Right to TryLaw exists; no usable Lilly retatrutide process verifiedNo supply confirmedCertain patients with a life-threatening condition, no approved option or workable trial, and physician certification and consent; the drug must also qualifyNot verifiedFDA; no Lilly retatrutide process found
Regular prescription (in person or telehealth)No approved retail product—Not available as ordinary pharmacy treatment—Lilly FAQ
Compounding pharmacyFDA says retatrutide cannot be compounded under federal lawNot a Lilly-supplied productNot a lawful U.S. compounded-treatment path—FDA
"Research use only" sites, med spas, overseas "pharmacies" selling for personal treatmentNo approved U.S. retail treatmentNot verified; a seller's label or lab report does not establish Lilly supply or the vial's safetyNot a documented Lilly access pathThe price shown is for an unapproved productFDA, Lilly
Wait for approvalFuture approval and launch are unconfirmedA Lilly product would require approval and commercial supplyA clinician would assess the approved label; insurance coverage would be a separate questionNo commercial price announcedLilly, July 23, 2026

One honest limit before you go further: no web page, including this one, can tell you that you qualify or hold a spot for you. The study team screens trial candidates; your doctor starts an expanded-access request, which still needs Lilly's agreement and FDA authorization. What this page can do is tell you which door to knock on, and exactly what to say when you do.

Which door fits you?

Find the row that sounds most like you. It's a starting point, not a medical decision. BMI means body mass index, a number from your height and weight.

Which door fits you?
If this sounds like youYour first stepWhat this won't do
You've been told you have fatty liver disease linked to weight or blood sugar, and you can reach a study siteAsk the SYNERGY-Outcomes study team whether its retatrutide part is screening near you (script below)Promise you get retatrutide; you could get placebo
Your BMI is 35 or more, you've taken and tolerated the highest available dose of an approved weight medicine, and two serious weight-related conditions are being treatedBring the five expanded access rules to the doctor who treats you (script below)Get you approved; Lilly decides case by case
You're on Zepbound, Wegovy, or Mounjaro, you've stalled, and your BMI is under 35Talk with your prescriber about next steps. With high-risk fatty liver disease, ask whether a trial could fitA BMI under 35 rules out the posted expanded-access criteria, not every trial. SYNERGY excludes BMI under 25; its other rules still apply
You just want to start something real this monthCompare approved options and prices (see below)Get you retatrutide
Someone offered you "reta" online, at a gym, or at a med spaDon't buy it; read the section on online sellers—
You're under 18, pregnant or planning to be, or have type 1 diabetes or a history of an eating disorderStart with your own doctor before any weight-loss medicine—

The right GLP-1 path isn't the same for everyone, even when retatrutide is off the table. It depends on your state, your insurance and its drug list, whether you'd take an FDA-approved or compounded medicine, a shot or a pill, and your budget. Compounded medicines are not FDA-approved. The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows a suggested provider path and pricing to review. It's free, takes about 2 minutes, and needs no signup. It doesn't apply for retatrutide or check your actual coverage.

If neither retatrutide door looks open for you, use it to compare available care before you choose a provider.

See which GLP-1 path fits you

Can a doctor prescribe retatrutide?

Not as a regular U.S. pharmacy prescription. Retatrutide has no FDA approval or approved prescribing label. A telehealth visit does not change that; a doctor can instead discuss a trial or a properly authorized expanded-access request (FDA, Lilly Medical).

You may hear "off-label." That's when a doctor uses an approved drug in a way the label doesn't list, like a different condition or dose (FDA). Retatrutide isn't approved for anything, so there's no "off" to prescribe it from.

You'll also see it called "GLP-3." Lilly calls that nickname scientifically inaccurate. Retatrutide is one molecule that acts on three hormone receptors (GIP, GLP-1, and glucagon), so the right term is "triple agonist" (Lilly). When a seller puts "GLP-3" on a label to sound official, slow down.

Path 1: Is any retatrutide trial taking new people?

Almost none. In our October 16, 2026 search of ClinicalTrials.gov, the only Lilly-sponsored retatrutide trial marked "Recruiting" was SYNERGY-Outcomes, a long study in people with high-risk fatty liver disease. That is the study's overall registry status. It doesn't mean a site near you has a retatrutide spot.

Here's what the registry showed. We searched for retatrutide studies marked Recruiting, Not yet recruiting, Enrolling by invitation, or Available, then checked the studies named on our earlier page too. The first three rows were returned by that filtered search. Open the closed-study list below to check a trial name from an older article.

Path 1: Is any retatrutide trial taking new people?
StudySponsorStatus on Oct 16, 2026Registry last updatedWho it studies / approximate participationTreatment assignment
SYNERGY-Outcomes, NCT07165028Eli LillyRecruitingOct 8, 2026High-risk fatty liver disease; ask about RT01. About 224 weeks, with an optional two-year extensionRetatrutide or placebo in RT01; tirzepatide or placebo in TZ01
Expanded access, NCT07629401Eli LillyAvailableAug 6, 2026All five rules in Path 2; individual treatment, not an enrolling trialRetatrutide if access is authorized; no placebo
NCT07467447Hudson BiotechRecruitingMar 12, 2026Phase 2 obesity study in Shenzhen, China; Lilly connection, drug source and local authorization not verifiedRecord lists retatrutide and placebo; this listing does not verify Lilly supply
Other named trials: completed or closed to new participants
Evidence table
StudySponsorStatus on Oct 16, 2026Registry last updatedWho it studies / approximate participationTreatment assignment
TRIUMPH-1, NCT05929066Eli LillyCompletedAug 21, 2026Obesity/overweight without type 2 diabetes, with knee-pain and sleep-apnea subsets; about 89 weeks, plus an optional 24-week extension for a subsetRetatrutide or placebo in the main study
TRIUMPH-2, NCT05929079Eli LillyCompletedJul 30, 2026Type 2 diabetes with obesity/overweight, with a sleep-apnea subset; about 89 weeksRetatrutide or placebo
TRIUMPH-3, NCT05882045Eli LillyCompletedJul 30, 2026Obesity with established cardiovascular disease; about 113 weeksRetatrutide or placebo
TRIUMPH-4, NCT05931367Eli LillyCompletedJan 21, 2026Obesity/overweight with knee osteoarthritis; about 77 weeksRetatrutide or placebo
TRIUMPH-5, NCT06662383Eli LillyActive, not recruitingJul 20, 2026Head-to-head comparison in adults with obesity; about 89 weeksRetatrutide or tirzepatide; no placebo
TRIUMPH-6, NCT06859268Eli LillyActive, not recruitingMar 3, 2026Weight-loss maintenance; about 125 weeksAll start retatrutide; some later receive placebo
TRIUMPH-7, NCT07035093Eli LillyActive, not recruitingSep 25, 2026Obesity/overweight with chronic low back pain (what the retatrutide studies say about back pain); about 80 weeksRetatrutide or placebo
TRIUMPH-8, NCT07232719Eli LillyActive, not recruitingApr 17, 2026Obesity/overweight without type 2 diabetes; about 65 weeksRetatrutide or placebo
TRIUMPH-9, NCT07357415Eli LillyActive, not recruitingJun 9, 2026Different dose-escalation schedules without type 2 diabetes; about 113 weeksAll three groups receive retatrutide; no placebo
TRIUMPH-Outcomes, NCT06383390Eli LillyActive, not recruitingOct 8, 2026Obesity/overweight with cardiovascular and/or kidney disease; about five yearsRetatrutide or placebo
TRANSCEND-T2D-1, NCT06354660Eli LillyCompletedMar 5, 2026Type 2 diabetes with blood sugar above target; about 11 monthsRetatrutide or placebo
TRANSCEND-T2D-2, NCT06260722Eli LillyActive, not recruitingSep 28, 2026Type 2 diabetes on metformin, with or without an SGLT2 inhibitor; about 26 monthsRetatrutide or semaglutide; no placebo
TRANSCEND-T2D-3, NCT06297603Eli LillyActive, not recruitingJul 20, 2026Type 2 diabetes with kidney impairment while using basal insulin; about 14 monthsRetatrutide or placebo

“Active, not recruiting” means the study is still running but closed to new participants. The times above describe participation, not an approval date or guaranteed access. Each linked official record is the source for its row. An SGLT2 inhibitor is a type of diabetes medicine; basal insulin is long-acting insulin.

Want every retatrutide study, results and all? See our full retatrutide trial tracker.

What SYNERGY-Outcomes actually is

SYNERGY-Outcomes isn't a weight-loss sign-up. It tests whether retatrutide or tirzepatide can prevent serious liver problems in adults with high-risk MASLD, which stands for metabolic dysfunction-associated steatotic liver disease, or fatty liver tied to weight and blood sugar problems (registry record).

It's built as two studies under one roof. One part, called RT01, compares retatrutide with placebo. The other part, TZ01, compares tirzepatide with placebo. So the useful question isn't "Is SYNERGY open?" It's "Is the RT01 part screening at a site I can reach?"

The commitment is big:

  • About 4,500 adults, for about 224 weeks (a little over four years)
  • Up to about 25 to 30 clinic visits
  • Liver-fat and stiffness tests, plus an ELF blood test that helps assess liver scarring; the study team checks the required ranges at screening
  • Listed reasons you can't join include: another type of liver disease, a BMI under 25, past decompensated liver disease (such as belly-fluid buildup or liver-related confusion), losing more than 11 pounds in the 3 months before screening, an A1C above 10%, or type 1 diabetes. A1C is a blood test that reflects average blood sugar
  • After the main study, people who qualify can join an optional two-year extension where everyone gets retatrutide or tirzepatide

Say a study record says "Recruiting" and there's a site an hour away. You still don't know if the retatrutide part is taking people there, or if your liver tests fit. Only the site can tell you. Don't order tests or change any medicine just because a web page lists them. Ask the study team what records it needs before arranging screening.

What to ask the study team

Your first contact is a question, not a sign-up. Copy this, fill in your city, and send it to the contact on the study record.

Hi, I'm asking about SYNERGY-Outcomes, NCT07165028. Is the retatrutide part of the study, RT01, screening new participants at a site near [your city] right now? What records would you need from me before deciding whether screening makes sense? Could you also explain the chance of getting placebo, how many visits are required, what costs are covered or reimbursed, and what happens with my care after the study ends?

The record lists Lilly's trial line, 1-877-CTLILLY (1-877-285-4559), and LillyTrials@Lilly.com. Ask the team how to send medical records securely rather than attaching them to an ordinary email. This is the trial line. The expanded access line in Path 2 is a different number, and it's for doctors.

Found a possible fit? Confirm the retatrutide opening with the study's listed team before you plan any travel.

See the official study contacts

If you're on a weight-loss medicine now, don't stop it to try to qualify for a trial. Let the study team review your medicines with the doctor who prescribes them. If you're weighing a switch, see switching from tirzepatide to retatrutide or switching from semaglutide to retatrutide.

Path 2: Lilly's expanded access — who qualifies and how your doctor asks

Lilly's expanded access program (NCT07629401) can give retatrutide to an adult who meets all five posted rules, including a BMI of 35 or more despite taking and tolerating the highest available dose of a weight-management medicine. Your treating doctor makes the request, and Lilly reviews each case on its own.

Expanded access is sometimes called compassionate use. It is treatment outside a trial for a serious or life-threatening condition when there is no comparable or satisfactory option and the possible benefit justifies the risks (FDA).

Here are the five rules from the official record, in plain English. All five have to be true.

Path 2: Lilly's expanded access — who qualifies and how your doctor asks
The ruleWhat it meansWhat trips people up
1. Age 18 or olderAdults onlyAge alone qualifies no one
2. Refractory obesity: BMI of 35 or more despite sticking with and tolerating the highest available dose of a chronic weight-management medicineYou took the top dose as prescribed, handled it, and your BMI is still 35 or more"I want something stronger" isn't the same thing. Neither is the highest dose you could handle, if that's lower than the top dose
3. Two or more serious or life-threatening weight-related conditions, being treated right nowAt least two serious health problems tied to weight, with standard care underwayTwo diagnoses on a chart aren't automatically two serious conditions under treatment
4. Can't join a retatrutide or similar trial, because you don't fit its rules or there's no enrolling site you can reasonably reachA trial isn't a real option for youNo reasonably accessible enrolling site can count, not just medical reasons; comparable investigational trials also matter
5. All standard options, including weight-loss surgery, discussed with youYou and your doctor talked through everything elseIt's a conversation. You don't have to have surgery

Anyone with a medical reason not to take retatrutide is excluded. Meeting the five rules is not a promise: Lilly also considers geography, supply, and the individual case (Lilly Medical).

Say you're 55, your BMI is 38, you've been on the top dose of Zepbound for a year and stalled, and you're being treated for sleep apnea and high blood pressure. That's a history worth bringing to your doctor. It isn't proof you qualify. Your doctor and Lilly still judge whether both conditions meet the "serious" rule and whether a trial is truly out of reach.

How the request works

  1. You talk with the doctor who treats you. Lilly's record says patients should go to their own doctor, not call Lilly.
  2. Your doctor calls the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979).
  3. If the first details fit, Lilly sends a detailed intake form. Lilly says it responds within five business days once it has the request and the medical information it needs (Lilly). A response is not an approval.
  4. If Lilly agrees, your doctor does the paperwork. That means a letter of agreement with Lilly, a request to the FDA with your doctor acting as the "sponsor," and approval from an ethics board (an IRB, which protects patients) (Lilly Medical).
  5. The FDA must authorize the request before Lilly can ship the medicine. You also give informed consent after the risks and treatment plan are explained.
  6. Lilly does not ship directly to patients. The treating team must arrange secure storage, dispensing, returns, and safety reporting.

That's real work for a doctor's office. A busy primary care practice may not be set up for it. A hospital obesity clinic or a practice that already runs research may be. If your doctor can't take it on, ask who can.

Copy this into your patient portal or bring it to your visit:

Could we review whether Lilly's retatrutide expanded access program, NCT07629401, might fit me? I'd like to go over my current BMI, the weight medicines I've taken and at what doses, the conditions I'm being treated for, any trials near me, and the other options we've discussed, including surgery. I understand this isn't an approval. Could your practice manage the request and the monitoring it needs, or refer me to a team that can? Before we start, what costs should I expect for visits, tests, or other care?

Think you might fit all five rules? Bring the whole picture to your doctor, not just a BMI number. Our early-access guide has a doctor checklist and blank worksheet built for that visit.

Open the doctor checklist

One thing that confuses people: Lilly's public FAQ, updated in September 2026, still says retatrutide is legally available only through Lilly's trials (Lilly FAQ). Lilly's medical-information page and the official registry record describe the expanded access program. Both are Lilly. We're showing you both so your doctor isn't caught off guard.

What does getting retatrutide cost?

Lilly says it provides retatrutide at no cost through expanded access. That doesn't mean all the care around it is free, and no commercial price has been announced. An online seller's monthly price is not the price of an approved retatrutide medicine.

Think of it like a free concert ticket. The ticket is free. Parking and gas still cost money.

What does getting retatrutide cost?
What you'd pay forWhat we foundWhat to ask
Retatrutide through expanded accessLilly says it provides the product at no cost (Lilly Medical)Is anything about handling or shipping billed?
Doctor visits, labs, monitoring, ethics review, travel under expanded accessNo patient-specific amount verifiedWho bills each one, and does my insurance pay? An unknown cost isn't a $0 cost
Being in a clinical trialNo patient-specific cost or reimbursement schedule verified for SYNERGYWhich study costs are covered, what's billed to me or my insurance, and is travel reimbursed?
Retatrutide after approvalNo price announced (Lilly FAQ)Check back after an approval and a price announcement
Medicare coverage for retatrutideRetatrutide is not on the Medicare GLP-1 Bridge list; listed products are Foundayo, Wegovy injection and tablets, and Zepbound KwikPen for eligible patients (CMS)Ask separately about coverage for visits and tests; the drug list does not answer that

Lilly says expanded access ends after possible FDA approval and commercial availability. Ask your doctor what the plan would be after that. For estimates clearly separated from announced prices, see retatrutide cost predictions.

For the Medicaid-specific question, see whether Medicaid will cover retatrutide.

Can you buy retatrutide online or from a compounding pharmacy?

Not as approved U.S. retail treatment. The FDA says retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. A "research use only" label or a seller's lab report does not make a product approved medicine or establish the safety of your vial (FDA).

For the LillyDirect-specific answer, see is retatrutide on LillyDirect?.

Here's what's on the record:

  • The FDA has warned telehealth companies for marketing retatrutide, ingredient distributors for selling it to compounders, outsourcing facilities for repackaging it, and companies selling it as "for research purposes" or "not for human consumption" while giving dosing instructions.
  • Lilly sued six U.S. sellers in August 2026, saying they sold retatrutide for people to use while labeling it for research (Lilly). See our retatrutide lawsuits tracker.
  • A health department reported liver injuries. Victoria, Australia, reported six cases of acute liver injury in people who used unapproved products labelled Retatrutide, Reta, R-10, or R-20. Officials said a contaminant may be involved, and testing was ongoing (Victoria Department of Health, June 19, 2026). That shows harm after people used products with the retatrutide name. It doesn't show what was in them.
  • A later regulator test found a different drug. On September 14, 2026, Australia's TGA reported testing a product sold as retatrutide after a serious adverse-event report. The sample contained semaglutide and no retatrutide (TGA). That finding concerns the tested product, not every vial or Lilly's trial medicine.

Watch for these phrases: "pharmacy-grade reta," "compounded GLP-3," "same as Lilly's," "FDA-compliant retatrutide," "available in all 50 states." A clinician's name on a retail order does not make an unlawful compounded product legal.

Why can't a pharmacy make it?

For patient-specific compounding under section 503A, FDA describes a sequence of ingredient rules: meet an applicable USP or NF quality standard; if no such standard exists, use a component of an approved drug; if neither applies, the substance must be on the 503A bulk-substances list. Retatrutide meets none of those conditions. These ingredient rules are not the only requirements for lawful compounding.

For section 503B outsourcing facilities, the ingredient must be on FDA's clinical-need bulks list, or the drug made from it must be on FDA's shortage list at the relevant times of compounding, distribution and dispensing. Retatrutide fits neither (FDA warning letter). A bulks list is not approval of a finished medicine. The full breakdown, including questions to ask any seller, is in our compounded retatrutide guide.

If you already took something labeled retatrutide

No judgment, and no dosing advice. Three things matter:

  1. Tell your doctor exactly what you used, when, and how much. Bring the vial, label, packaging, and order page.
  2. Get help fast if symptoms are severe. In the U.S., if someone collapses, has a seizure, has trouble breathing, or can't wake up, call 911. For other questions about an unknown product, call Poison Control at 1-800-222-1222. In Australia, the Poisons Information Centre is 13 11 26. Yellow skin or eyes, dark urine, or other signs of liver injury also need prompt medical care (Victoria Department of Health).
  3. Report it to the FDA's MedWatch program.

Our guide to spotting fake GLP-1 medicines covers the warning signs. For what Lilly's trials found about side effects, see retatrutide side effects. An unknown vial may not match those results.

When will retatrutide be available by prescription?

No approval date has been set. Lilly said on July 23, 2026 that it planned to ask the FDA for approval in the first quarter of 2027, after finishing its manufacturing and quality data. It repeated the Q1 2027 plan in its September 29 announcement. A planned filing isn't an approval or a pharmacy launch.

The application type is disputed. Lilly's September announcement called its planned filing a Biologics License Application, or BLA. But an FDA letter dated October 2, 2026, filed in court on October 8, says retatrutide is a drug, not a biological product, and must use the drug-approval pathway under section 505. Lilly's October 8 court filing continued to seek biological-product classification. So “BLA, not NDA” is not a settled fact; an NDA is a New Drug Application. This dispute is about the filing path, not permission to sell retatrutide.

The FDA's review goals help set expectations, but the clock matters. For a new-molecular-entity NDA or an original BLA, the standard goal is action within 10 months of the 60-day filing date; priority review is 6 months from that date. That is roughly 12 or 8 months after FDA receives the application, not 10 or 6 months from submission (FDA review goals). “Action” can be a request for more work, not approval.

FDA also has a separate national-priority voucher pilot targeting a one- to two-month review for selected applications with advance work. We found no retatrutide priority-review designation or voucher announcement in the sources checked. None of these targets gives retatrutide an approval date. Even after approval, commercial supply, a price, and coverage decisions would still need to be confirmed.

Should you wait for retatrutide or start something now?

Whether to wait is a decision to make with your prescriber, not something a future weight-loss headline can settle. If your health is getting worse, make a care plan now: retatrutide's approval date, price, and coverage are unknown. Approved medicines are available, and using one does not stop you from asking about retatrutide later—though a trial can have medicine-use restrictions.

Here's why people want it. In TRIUMPH-1, adults without type 2 diabetes assigned to retatrutide 12 mg had an estimated average weight loss of 28.3% at 80 weeks under the analysis that assumes participants stayed on their assigned treatment, versus 2.2% with placebo. The analysis that counts participants in their assigned groups even if they stopped treatment or used other weight-loss treatment found 25.0% versus 3.9% (Lilly, May 21, 2026). These are two statistical questions, not a guarantee for someone who completes treatment.

Those are strong numbers. The peer-reviewed TRIUMPH-1 abstract also reports the 25.0% and 3.9% results; stomach and gut side effects were the most common. Comparisons drawn from separate trials cannot establish which medicine works best for you. See retatrutide vs. tirzepatide and retatrutide weight loss results.

Should you wait for retatrutide or start something now?
If this is youA sensible next step
"I only want real retatrutide."Check SYNERGY-Outcomes, ask your doctor about expanded access, and put a reminder on your calendar for spring 2027 to check whether Lilly has filed.
"I need help now and I'm not close to the expanded access rules."Talk to a licensed prescriber about approved options this month.
"I'm on Zepbound or Wegovy and stuck."Ask your prescriber about next steps. See best GLP-1 after Zepbound, after Wegovy, and our GLP-1 non-responder research.
"I'd rather take a pill."Foundayo is an FDA-approved once-daily tablet for weight management, approved April 1, 2026 (FDA). It's a different medicine from retatrutide. See Foundayo reviews.
"I have Medicare."Start with Medicare's eligibility steps and your prescriber. The Medicare GLP-1 Bridge gives eligible Part D enrollees Foundayo, Wegovy injection or tablets, or Zepbound KwikPen for a $50 monthly copay through December 31, 2027. It operates outside normal Part D coverage and requires prior authorization. Your prescriber and pharmacy handle that process. See our Medicare GLP-1 Bridge guide.
"I have Medicaid."Start with your state plan's rules: what GLP-1s Medicaid covers.
"I'm weighing surgery."See GLP-1 vs. bariatric surgery.

For more choices side by side, see the best retatrutide alternatives.

If cost is why you looked at online vials

Brand-name prices can make online vials look tempting. With commercial insurance, check what your plan actually covers before assuming approved treatment is out of reach. Your plan's member portal or pharmacy-benefits number is a direct place to start. Ro also offers a free report using information from your insurance card; no prescription is needed for that check.

Ro checks benefits for Ozempic and Wegovy pens and the Zepbound single-dose pen, then emails you a report. Ro calls your insurer to collect coverage details. The check does not write a prescription, submit a treatment request, or guarantee payment. It can't check the Zepbound KwikPen, Foundayo pill, or Wegovy pill. Ro says new accounts also get a $50 Ro credit with the free report (Ro).

Check your coverage with Ro (sponsored affiliate link, opens in a new tab)

No coverage, or no insurance? Then compare the cash price plus the cost of care. Here are Ro's advertised charges, checked October 16, 2026, with the manufacturer offer limits alongside them. Membership and medicine are separate charges; this is not a personal checkout quote.

If cost is why you looked at online vials
ChargeWhat Ro listed on Oct 16, 2026; important offer limits
Membership, first month$39 to start; Ro says it refunds the initial purchase if no medication is prescribed and you are not enrolled
Membership after that$149/month on the monthly plan, or prepaid: $99/month for 3 months ($297 upfront), $89/month for 6 months ($534 upfront), $74/month for 12 months ($888 upfront). Those are monthly equivalents, not monthly installments
Wegovy pill (FDA-approved), 30-day supply$149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg). The lower doses are for starting and building up treatment, not lower-cost maintenance choices
Foundayo pill (FDA-approved), 30-day supply$149 (0.8 mg); $149 (2.5 mg) and $199 (5.5 mg) under price reductions through Dec 31, 2026; $299 (9 mg); $299 (14.5 mg and 17.2 mg) with the purchase offer and its 45-day refill rule
Wegovy pen (FDA-approved), 28-day supply$199 for the first two eligible fills of 0.25 mg or 0.5 mg under the new-patient offer through Dec 31, 2026; regular self-pay price $349 for 0.25 mg through 2.4 mg; $399 for 7.2 mg
Zepbound KwikPen (FDA-approved), 28-day supply$299 (2.5 mg), $399 (5 mg), $449 (7.5 mg to 15 mg) with the manufacturer purchase offer and its 45-day refill rule. Pen needles are not included in the manufacturer's price

Sources: Ro pricing, Ro membership terms, NovoCare's Wegovy terms, and Lilly's Foundayo and Zepbound terms. Ro says its cash prices match LillyDirect, NovoCare, and TrumpRx. That's Ro's claim, not a comparison we ran.

The offer limits change the bill. For Foundayo 14.5 mg or 17.2 mg and Zepbound KwikPen 7.5 mg through 15 mg, Lilly's purchase offer applies to the first eligible fill; later refill purchases must be within 45 days of delivery or receipt of the previous fill. Without that offer, Lilly lists Foundayo 14.5 mg and 17.2 mg at $349, Zepbound 7.5 mg at $499, and Zepbound 10 mg, 12.5 mg and 15 mg at $699 per supply. These are Lilly's regular prices, not a Ro checkout quote.

The temporary Foundayo prices for 2.5 mg and 5.5 mg run through December 31, 2026; regular prices are $199 and $299. Wegovy's $199 starter-pen offer also applies only to eligible fills through that date. Signing up before the deadline does not lock in those prices indefinitely. A 28-day injection supply is four weeks, not a calendar month. Taxes, fees or supplies can add to the bill; we did not verify a shipping charge for your order.

Before you prepay: Ro's paid membership fees are non-refundable and renew automatically, even without a medication fill. Cancel at least 48 hours before renewal to avoid the next membership charge; care continues through the paid billing period. Membership includes up to 24 medical consults per year, messaging and clinician-ordered program labs. Extra consults after that are $15 each; additional lab charges depend on the test. Medication is separate for the advertised plans here; drug refunds or replacements follow the dispensing pharmacy's policy (Ro terms).

Say your prescriber starts you on the lowest dose of the Wegovy pill and you qualify for the advertised introductory price. The first membership charge plus one 30-day medicine supply is $39 + $149 = $188, before any additional fees. The Wegovy label lists 25 mg as the pill's maintenance dose. At that dose, Ro's posted medicine price is $299; paired with a $149 monthly membership charge, that is $448, before extras. These are cost examples, not instructions for choosing or changing a dose. The 12-month plan lowers membership to $74 a month, but you pay $888 up front, with medicine still separate.

Already have a prescriber? Ask about sending an eligible prescription to the manufacturer's self-pay pharmacy option without adding a Ro membership. Your own clinician may still charge for care (Lilly programs, NovoCare).

Need a telehealth prescriber and ongoing care instead? Review Ro's program and starting prices, then check the full medication and membership charges before enrolling.

See Ro's program and starting prices (sponsored affiliate link, opens in a new tab)

Prefer to compare more providers, including compounded options? Compounded medicines are not FDA-approved, and they aren't retatrutide. Find My GLP-1 Path lets you say what you're open to and shows a suggested path to review. You can also read our Ro review and our guide to compounded vs. brand-name GLP-1s.

Is retatrutide available in the UK, Canada, or Australia?

Lilly says retatrutide has not been approved by any regulator (Lilly FAQ). Trials run in many countries, but a study site in your country isn't the same as routine pharmacy availability. Outside the U.S., doctors ask their local Lilly office about expanded access; local authorization and Lilly's agreement are required before supply (Lilly).

The five rules on this page come from the U.S. registry record, so don't assume they're the same everywhere. And an import rule doesn't turn an online vial into approved medicine. Australia's liver-injury alert involved unapproved products bought online, from friends, or through social media.

What we actually verified

We checked FDA records, Lilly and Novo Nordisk sources, CMS, the federal trial registry, and Ro's own pages on October 16, 2026. We also read the TRIUMPH-1 journal abstract and Australian safety alerts. We did not call study sites, contact Lilly, submit an application or checkout, buy a product, or use retatrutide.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Read how we evaluate.

Checked October 16, 2026:

  • FDA's statement on unapproved GLP-1 drugs (content current as of Oct 1, 2026), for retatrutide's compounding status and warnings
  • FDA pages on off-label use, expanded access, Right to Try and Foundayo's approval; the PDUFA VII review goals and national-priority voucher pilot
  • FDA's October 2, 2026 classification letter and Lilly's October 8 filing, read as primary documents filed in court, not as a news summary
  • The expanded access record NCT07629401 and Lilly's medical-information page on the program (last reviewed by Lilly Aug 26, 2026), plus Lilly's expanded access policy
  • A ClinicalTrials.gov search for retatrutide studies that are Recruiting, Not yet recruiting, Enrolling by invitation, or Available, plus the official records for every study in the table, including TRANSCEND-T2D
  • Lilly's public retatrutide FAQ (updated September 2026), its July 23 and September 29, 2026 filing statements, its May 21 TRIUMPH-1 results, and its August 12 lawsuit announcement; the September 29 TRIUMPH-1 journal abstract for its reported outcomes
  • CMS's Medicare GLP-1 Bridge provider page (last modified Aug 6, 2026) and Medicare.gov's patient eligibility and pharmacy steps
  • Victoria Department of Health's June 19, 2026 alert, TGA's September 14 tested-product alert, and U.S. Poison Control's emergency guidance
  • Ro's live pricing page, membership terms and free insurance coverage checker; Lilly and NovoCare manufacturer offer terms; the product-label sections confirming the formats listed and Wegovy pill maintenance dose. These are published terms, not prices we paid or a coverage report we received.

Source differences that matter: The trial-only wording in Lilly's public FAQ and its separate expanded-access documents differ, as explained in Path 2. Lilly's filing plan also differs from FDA's October 2 classification decision, as explained in the timeline section. Ro's short promotional wording must be read with the manufacturers' full offer terms.

What we couldn't confirm: an approval date or price; how many expanded access requests Lilly has approved; whether a given SYNERGY site is screening the RT01 part this week; what visits, labs, or travel would cost you; or what your insurance will cover. This page has no medical reviewer.

How to get retatrutide: questions people ask

How are people getting retatrutide?

Two documented Lilly paths are a clinical trial and its expanded-access program, which your doctor requests. Products sold online for personal treatment are not a substitute for either path; FDA warns against unapproved sales, and a seller's label does not establish the vial's identity, strength or safety (FDA).

Can I buy retatrutide peptide in the USA?

Not as approved retail medicine for personal treatment. "Research use only" products are not approved medicine, and FDA has warned companies that sell them for people to use. A laboratory-research label is not a treatment authorization.

Is retatrutide available in the USA?

Not as an ordinary pharmacy prescription. As of October 16, 2026, the documented Lilly options to investigate are trial screening—SYNERGY-Outcomes was the recruiting record found—and physician-requested expanded access. Site availability and individual review still apply.

Can I get a prescription for retatrutide?

Not a regular U.S. pharmacy prescription. Retatrutide is not FDA-approved, and off-label prescribing applies to approved drugs used in unapproved ways. A properly authorized expanded-access treatment plan is different from routine prescribing.

Can I join a trial while I'm on Zepbound, Wegovy, or Mounjaro?

It depends on the study. SYNERGY-Outcomes lists losing more than 11 pounds in the 3 months before screening as a reason you can't join. Let the study team review your medicines with your prescriber, and don't stop a prescribed medicine to try to qualify.

Will I definitely get retatrutide in a trial?

No. SYNERGY-Outcomes' retatrutide part compares retatrutide with placebo, so you could get placebo. TRIUMPH-9 has no placebo—all three groups receive retatrutide—but it is closed to new participants. Ask about treatment assignment in the exact study part you are considering.

What if there's no trial near me?

Ask the official study contact about sites you could realistically reach. No reasonably accessible enrolling site can satisfy the trial-access part of the expanded-access criteria, but retatrutide and comparable investigational trials must be considered. The other criteria and case-by-case review still apply.

Can I apply for expanded access myself?

No direct patient application is listed in Lilly's published process. Your treating doctor calls the Lilly Answers Center, and paying a clinic doesn't mean Lilly has accepted your case.

Is expanded access retatrutide free?

Lilly says it provides the drug at no cost. That doesn't cover who pays for your visits, labs, monitoring, or travel, so ask your doctor's office for a cost estimate before you start.

Is Right to Try another way to get it?

Not one we can verify. The federal Right to Try law doesn't require a drug company to provide its drug, and we found no Lilly retatrutide Right to Try process.

When will retatrutide be in pharmacies?

No confirmed date exists. Lilly's latest filing statements checked target Q1 2027, but the application classification is disputed. Standard and priority review goals run from the filing date after the initial 60-day review; they do not set a retatrutide approval or launch date.

How much will retatrutide cost?

No commercial price has been announced. Lilly says the product is free under expanded access, but other care costs need checking. An online seller's price or a future-price estimate is not an approved retail price.

For plan-by-plan insurance rules and costs around studies or expanded access, see who pays for retatrutide access.

Is retatrutide available as a pill?

No approved retatrutide pill exists. Lilly studies retatrutide as an injection; approved weight-loss pills are different medicines. See whether retatrutide comes as an approved pill for the product distinction.

Does retatrutide have an FDA boxed warning?

It has no FDA-approved label, so it has no FDA boxed warning. That is not proof of low risk—it means there is no approved prescribing label yet. See GLP-1 boxed warnings for how approved medicines are labeled.

Keep reading

Sources

Checked October 16, 2026. Dates in parentheses belong to the source.

  1. FDA — Concerns with unapproved GLP-1 drugs used for weight loss (content current as of Oct 1, 2026)
  2. ClinicalTrials.gov — Pre-approval expanded access of retatrutide, NCT07629401 (last update posted Aug 6, 2026)
  3. Lilly Medical — Is there an expanded access program for retatrutide? (last reviewed Aug 26, 2026)
  4. Eli Lilly — Expanded access policy
  5. ClinicalTrials.gov — SYNERGY-Outcomes, NCT07165028 (last update posted Oct 8, 2026)
  6. ClinicalTrials.gov — Retatrutide study search, including NCT07467447, TRIUMPH-5, TRIUMPH-7, TRIUMPH-8, TRIUMPH-9, TRIUMPH-Outcomes
  7. Eli Lilly — What to know about retatrutide (updated September 2026)
  8. Eli Lilly — Retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026)
  9. Eli Lilly — TRIUMPH-1 Phase 3 results (May 21, 2026)
  10. Eli Lilly — Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market (Aug 12, 2026)
  11. FDA — Understanding unapproved use of approved drugs "off label"
  12. FDA — Expanded access: information for patients
  13. FDA — Right to Try (content current as of Dec 12, 2024)
  14. FDA — Priority review
  15. FDA — Warning letter 715883, GLP-1 Solution (Sept 9, 2025)
  16. FDA — Foundayo approval under the national priority voucher program (April 1, 2026)
  17. CMS — Medicare GLP-1 Bridge: information for providers (last modified Aug 6, 2026) and Medicare.gov patient steps
  18. Victoria Department of Health — Toxicity linked to unapproved product labelled retatrutide (June 19, 2026)
  19. FDA — MedWatch
  20. Ro — Weight-loss program pricing and GLP-1 insurance coverage checker
  21. Ro — Terms of Use, Body Membership terms
  22. Eli Lilly — September 29 filing statement and TRIUMPH-2 release (September 29, 2026)
  23. FDA — Retatrutide classification determination (October 2, 2026; court-filed October 8, 2026)
  24. Eli Lilly — Supplemental appellate brief (October 8, 2026)
  25. FDA — PDUFA VII performance goals and national-priority voucher pilot
  26. TRIUMPH-1 investigators — Peer-reviewed study abstract (September 29, 2026)
  27. Novo Nordisk — Wegovy prescribing information and NovoCare savings terms
  28. Eli Lilly — Foundayo coverage and savings, Zepbound savings terms, and Zepbound prescribing information
  29. TGA — Tested product sold as retatrutide contained semaglutide (September 14, 2026)
  30. National Capital Poison Center — First aid for poisonings

Found an error? Email hello@therxindex.com, the contact listed in our corrections policy.

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.

Related guide: who qualifies for retatrutide early access

Related guide: can you get retatrutide through Ro?

Related guide: using HSA or FSA money for retatrutide

Your situation changes the answer

Find My GLP-1 Path

The right GLP-1 provider isn't the same for everyone. It depends on whether you'll use insurance or pay cash, whether you want an FDA-approved or compounded medication, your preferred route (injection or oral), and your budget. Answer a few questions in The RX Index's Find My GLP-1 Path tool to see a suggested provider route and pricing to review before you choose. It does not check your plan's coverage or copay; confirm those in your insurer's member portal or with the pharmacy-benefits number on your card.

  • What it asks: your goals, how you plan to pay, and your treatment preferences
  • What you get: a suggested provider route and pricing information to review
  • Cost: free · about 2 minutes · no signup
Find My GLP-1 Path